Novast Pharmaceuticals Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Novast Pharmaceuticals Ltd. - overview
Established
2005
Location
Nantong, Jiangsu, China
Primary Industry
Pharmaceuticals
About
Founded in 2005 and based in Jiangsu, China, Novast Pharmaceuticals Ltd. is a multinational pharmaceutical R&D and manufacturing company specializing in the research and development of drug delivery systems and sustained-release formulations. Through collaborations with U. S.
distributors and originator companies, it develops and manufactures generic drugs with sustained-release and other value-added formulations for sale in the U. S. pharmaceutical market. In January 2021, Novast Pharmaceuticals Ltd.
raised CNY 400 million in venture funding led by returning investor HighLight Capital, with participation from another returning investor Shiyu Capital. The company develops and manufactures generic drugs for the European, American, and Chinese markets. Revenue is generated through production and sale of generic drugs mainly in the U. S.
pharmaceutical market and other country.
Current Investors
New Enterprise Associates, SAIF Partners, Qiming Venture Partners
Primary Industry
Pharmaceuticals
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Pharmaceutical Research & Development
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.